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part of the gastrointestinal tract. Although most people with CD lead active lives, five 
years after onset 15% to 20% of patients are disabled by their disease to some degree. 
The purpose of the current review was to evaluate recent data from the literature on 
the economic burden of CD in European countries in adults and in children, using US 
data as a benchmark. Methods: A systematic review of the data on economic and 
humanistic burden for adults and children in Germany, France, UK, Italy, Spain and 
the US was performed covering the period 2000 to 2012. The methods followed rec-
ommendations and guidance published by the Centre for Reviews & Dissemination, 
York, UK. Results: Of the 425 publications identified on the economic burden of 
CD, 92 were suitable for further evaluation, and 39 were selected. Among these 
studies, five presented total costs of CD management in adults, ranging from € 1,425 
to € 15,521 per patient depending on the country. Most of the direct costs were due 
to hospitalisations, surgeries or use of biologic drugs. Patients with severe disease 
and those requiring hospitalisation had disproportionately higher costs (5.6 times 
higher) compared to those with milder disease. Direct costs were more important 
for relapsing disease than quiescent disease. Only one European study focused on 
children using biologic drugs as maintenance treatment. ConClusions: Research 
on the economic burden of CD management has been mainly published on adults 
in the US and UK, with limited data from Germany, Spain and Italy. Similar data for 
paediatric CD is almost non-existent. More research is needed to better understand 
the economic and humanistic burden faced by paediatric CD patients in Europe.
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objeCtives: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-
alcoholic fatty liver disease that becomes increasingly prevalent with the growing 
epidemic of obesity and diabetes in the United States. An estimated 3% of adults in the 
US have NASH and are at high risk of severe liver complications, including cirrhosis, 
liver failure, and hepatocellular carcinoma (HCC). Despite the rising prevalence, data 
on its economic and clinical consequences are limited. The objective of this study 
was to predict the long-term clinical and economic consequences associated with 
the adult NASH patients in the US over the next 20 years, including NASH-related 
complications, morbidity, mortality and health care costs. Methods: We developed 
a Markov cohort model to estimate the consequences of NASH, which included six 
Markov states: NASH, compensated cirrhosis, decompensated cirrhosis, HCC, liver 
transplantation, and death. We estimated the number of liver complications, their 
associated health care costs, and NASH-related mortality. Results: By 2033, 53.1% 
and 32.8% of NASH patients would progress to compensated and decompensated cir-
rhosis, respectively. An estimated 13.7% of patients developed HCC, and 13.3% eventu-
ally underwent liver transplantation. Among NASH patients, 16% had Type II diabetes 
and 44.8% and 23.8% would develop decompensated cirrhosis and HCC. The model 
predicted hepatic-related mortality of 24.2% and 12.6% for patients with and without 
diabetes, while the cardiovascular-related mortality was estimated to be 12.1% and 
8.8% for NASH patients with and without diabetes. The direct health care cost was 
estimated at $72,170 and $120,165 for patients with and without diabetes, resulting in 
a total of $574 billion health care cost over the next 20 years. ConClusions: NASH 
patients were expected to have substantial risks for chronic liver failure and result 
in an increasing financial burden on the US health care system.
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objeCtives: Undertake an economic evaluation of transjugular intrahepatic por-
tosystemic shunts (TIPS) compared to large volume paracentesis (LVP) in patients 
with refractory ascites. Paracentesis, although the standard treatment for refractory 
ascites, does not treat the underlying portal hypertension. According to a meta-
analysis of individual patient data, using TIPS with bare metal stents (BMS) rather 
than LVP showed improved survival and lower recurrence of ascites although with 
a higher number of hepatic encephalopathy episodes (Salerno 2007). Methods: A 
Markov economic model was developed to measure the incremental resources and 
costs associated with TIPS, using costs for ePTFE covered stent-grafts configured 
for TIPS (SG), compared to LVP over two years. Clinical data came mainly from the 
meta-analysis, whilst health care costs were from UK national databases. Results: 
Use of TIPS rather than LVP to manage refractory ascites was estimated to save 
almost £1,600 per patient over 2 years. Total costs for the treatment pathway were 
£8,310 with TIPS and £9,907 with LVP treatments. The TIPS implantation, together 
with the associated costs of re-intervention & complications cost £6,760 but there 
were estimated savings of £8,360 from avoided LVP procedures. Using TIPS to man-
age refractory ascites, rather than LVP, was cost saving under all the sensitivity 
analyses undertaken. ConClusions: The economic model demonstrated a total 
cost reduction of £1,600 per patient from TIPS with SG compared to LVP. Actual cost 
reduction may be greater as clinical data used from the meta-analysis was for BMS. 
Compared to BMS, SG have improved patency resulting in fewer reinterventions 
(Bureau 2007) which may reduce overall costs.
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were estimated using national average reference costs based on treatment speci-
ality. Costs of medications prescribed in secondary care were not included. Total, 
mean and annual visits and costs were estimated and stratified by gender, age and 
treatment speciality. Prices were adjusted to 2011/2012. Results: We identified 
79,303 patients with IBS with an average follow-up of 3.38 years. Of these patients, 
46,814(59%) had ≥ 1 contact with secondary care for any cause; 22,685(48.5%) patients 
attended outpatient services only. Patients using secondary care had about 2 hos-
pitalizations on average and 3-4 outpatient visits annually. Mean inpatient stay 
declined from 4 days in 2008/2009 to 3 days in 2011/2012. The total cost of hospi-
talisation during the period was over £114 million, including about £35(30%) million 
for emergency inpatient admissions and £33.8 million for outpatient attendance. 
Digestive disorders accounted for around 30% of inpatient admissions and 21% of 
expenditure incurred. Mean cost of inpatient admissions for digestive conditions 
was £1,993, average costs per patient was £4,871 and £2,779 for elective and emer-
gency visits respectively. ConClusions: Utilisation and costs of secondary care 
among IBS patients is substantial, not only for the management of IBS and related 
conditions, but also for other co-morbid medical conditions.
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objeCtives: There are approximately 40,000 Canadians living with spinal cord 
injury (SCI). Most individuals with SCI experience some type of bowel dysfunction 
(BD), which can contribute to a high burden in individuals and caregivers, and a 
decrease in quality of life. This study aims to identify and measure resources, costs, 
health preference and quality of life associated with BD and its management in a 
cohort of SCI individuals living in a community setting in Ontario over a 6-month 
period. Methods: This study is a prospective, observational study with 80 adult 
participants being recruited at three SCI clinics in Ontario, Canada. Questionnaires 
are completed by participants over a 6-month period (baseline, three weekly and 
five monthly). Information related to demographics, BD (e.g., neurogenic bowel 
dysfunction score), health preference (e.g., Health Utility Index (HUI) Mark 3) and 
resource utilization (e.g., physician, medication, caregiver burden, etc.) attributed 
to BD is being collected. Results: Results from three clinics are being evaluated. 
45 participants have completed the questionnaires to-date. The majority of partici-
pants are male (60.00%). Mean time since SCI was 20.2±13.7 (2 – 42) years. Twenty 
(44.4%) participants were employed. At baseline, the mean neurogenic BD score was 
14.37±6.05 (0 – 31). At 6 months, the score was 12.9±6.6 (2 – 28). The mean HUI-3 score 
at baseline was 0.17±0.31 (-0.37 – 0.95). At 6 months the score was 0.19±0.33 (-0.37 – 
1). The mean number of visits to primary care physicians by participants was 8.3 ± 
8.6 (0 – 33) times over 6 months. 52.21% of participants required caregiver assistance. 
12.50% of participants required a mean 1.21±0.67 (0.3 – 2) hours daily assistance 
with their bowel routines. ConClusions: Results from the 45 SCI individuals with 
BD indicate a variety of health resources are being utilized over a 6-month period. 
Future results will have resources associated with BD quantified.
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objeCtives: Hepatitis C virus infection is accompanied by significant disease and 
economic burden internationally. In absence of data, the objective of this study 
was to estimate the annual cost of hepatitis C treatment and follow-up, in Greece, 
according to disease severity. Methods: Resource utilization for “typical patient” 
scenarios, according to disease stage, was elicited via an expert panel (gastroen-
terologists and hepatologists from major hospital units of the Greek NHS). Patients 
were stratified based on disease stages; (a) fibrosis stage F0 to F3, (METAVIR score) (b) 
compensated cirrhosis (c) decompensated cirrhosis – first year (d) decompensated 
cirrhosis – subsequent years (e) hepatocellular carcinoma (HCC) (f) liver transplant 
(LT) – first year (g) LT – subsequent years. Direct cost categories included yearly 
costs of consultations, laboratory and PCR tests, medications and hospitalization. 
Cost calculations were based on 2012 fixed fees and prices, from a Social Security 
perspective. Results: The average direct annual cost per patient for F0-F3 patients 
was estimated at 642.7€ , excluding the cost of medications or 12,685.1€ , includ-
ing the cost of standard of care with PegIFN/ribavirin regimen. Respective annual 
costs for states (b) to (g) were: 636.7€ (compensated cirrhosis), 2,250.1€ and 5,934.5€ 
(decompensated first and subsequent years), 21,890.1€ (HCC), 35,051.1€ and 4,001.5€ 
(LT first and subsequent years). Main cost variables were hospitalizations [48.9%, 
53.3% and 88.2% of the total cost for states (c) (d) and (g)], medications [93.2% and 
50.1% of the total cost for states (e) and (g)] and laboratory tests [89.1% and 83.0% 
of the total cost for states (a) and (b)]. ConClusions: This cost analysis of chronic 
hepatitis C in the Greek health care system has shown that there is a substantial 
economic burden, significantly increasing in advanced liver disease. Standard and 
new interventions that slow disease progression or achieve virus eradication are 
deemed necessary from a clinical and economic perspective.
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objeCtives: Crohn’s Disease (CD) is an immune-mediated disorder characterised by 
recurrent chronic uncontrolled inflammation on the intestinal mucosa affecting any 
